指南与共识瓣膜病与结构性心脏病

拉丁美洲重度主动脉瓣狭窄经导管与外科瓣膜置换临床实践指南

Clinical practice guideline for transcatheter versus surgical valve replacement in patients with severe aortic stenosis in Latin America.
指南 / 共识 · Heart · 2021-06-14

该指南针对居住在拉丁美洲、75岁及以上、有症状的重度主动脉瓣狭窄且适合经股动脉途径的患者,建议优先选择经导管主动脉瓣植入(TAVI)而非外科主动脉瓣置换(SAVR)。这一推荐为条件性推荐,基于中等确定性证据。推荐不适用于已有标准治疗的患者,如心脏手术极高危或不可手术者应选TAVI,非老年(如65岁以下)低危者应选SAVR。

要点

  • 75岁及以上经股动脉候选者建议优先TAVI而非SAVR(条件性推荐,中等确定性证据)。
  • 推荐不适用于已有标准治疗者:极高危/不可手术选TAVI,65岁以下低危选SAVR。
  • 75岁阈值基于有限文献判断,应作为参考而非决定性界限。

核心结论

  • 对于居住在拉丁美洲、75岁及以上、有症状的重度主动脉瓣狭窄且适合经股动脉途径的患者,专家组建议使用TAVI而非SAVR。

研究设计与样本

  • 本文件为临床实践指南,由专家组制定,针对拉丁美洲重度主动脉瓣狭窄患者经导管与外科瓣膜置换的选择。

主要发现

  • 推荐为条件性推荐,基于中等确定性证据(⨁⨁⨁Ο)。
  • 推荐不适用于已有标准治疗的患者,如心脏手术极高危或不可手术者应选TAVI,非老年(如65岁以下)低危者应选SAVR。
  • 建议的75岁年龄阈值基于对有限可用文献的判断,应作为指南而非决定性阈值。

关键数值与推荐

  • 推荐条款:75岁及以上经股动脉候选者建议优先TAVI而非SAVR(条件性推荐,中等确定性证据⨁⨁⨁Ο)。
  • 推荐不适用于已有标准治疗者:极高危/不可手术选TAVI,65岁以下低危选SAVR。
  • 75岁阈值基于有限文献判断,应作为参考而非决定性界限。

临床怎么用

  • 临床医生应熟悉支持该推荐的证据,并通过心脏团队多学科讨论、结合患者价值观与偏好及可用资源,帮助每位患者达成管理决策。
  • 政策制定者实施该推荐需要充分辩论和多方利益相关者参与。

局限性

  • 建议的75岁年龄阈值基于对有限可用文献的判断。
  • 推荐为条件性,意味着多数患者会倾向经股动脉TAVI而非SAVR,但部分患者可能偏好SAVR。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In elderly (75 years or older) patients living in Latin America with severe symptomatic aortic stenosis candidates for transfemoral approach, the panel suggests the use of transcatheter aortic valve implant (TAVI) over surgical aortic valve replacement (SAVR). This is a conditional recommendation, based on moderate certainty in the evidence (⨁⨁⨁Ο).This recommendation does not apply to patients in which there is a standard of care, like TAVI for patients at very high risk for cardiac surgery or inoperable patients, or SAVR for non-elderly patients (eg, under 65 years old) at low risk for cardiac surgery. The suggested age threshold of 75 years old is based on judgement of limited available literature and should be used as a guide rather than a determinant threshold.The conditional nature of this recommendation means that the majority of patients in this situation would want a transfemoral TAVI over SAVR, but some may prefer SAVR. For clinicians, this means that they must be familiar with the evidence supporting this recommendation and help each patient to arrive at a management decision integrating a multidisciplinary team discussion (Heart Team), patient's values and preferences through shared decision-making, and available resources. Policymakers will require substantial debate and the involvement of various stakeholders to implement this recommendation.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Lamelas P, Ragusa MA, Bagur R, et al. Clinical practice guideline for transcatheter versus surgical valve replacement in patients with severe aortic stenosis in Latin America. Heart. 2021. PMID: 34127541. doi:10.1136/heartjnl-2021-319489

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。